Discontinue therapy if markedly elevated creatine phosphokinase levels occur or myopathy is diagnosed or suspected; in new onset or aggravated pre-existing myasthenia gravis or ocular myasthenia; throughout duration of fusidic acid treatment in patients where use of systemic fusidic acid is essential; patients develop symptoms of myalgia at calf, back or body; transaminase levels rise to >3x ULN. Temporarily withhold or discontinue therapy in patient w/ acute, serious condition suggestive of myopathy or having risk factor predisposing to development of renal failure secondary to rhabdomyolysis (eg, severe acute infection, hypotension, major surgery, trauma, severe metabolic, endocrine & electrolyte disorders & uncontrolled seizures). Promptly interrupt therapy if serious liver injury w/ clinical symptoms &/or hyperbilirubinemia or jaundice occurs during treatment. Temporarily suspend use in patients taking daptomycin. Rhabdomyolysis w/ acute renal failure secondary to myoglobinuria. Increased risk of higher blood sugar levels. Patients who consume substantial quantities of alcohol &/or have history of liver disease; w/ recent stroke or transient ischemic attack; w/ alcoholism, or hypothyroidism. Closely monitor patients w/ history of renal impairment for skeletal muscle effects. Carefully monitor patients for signs or symptoms of muscle pain, tenderness or weakness particularly during initial mth of therapy & any periods of upward dosage titration. Obtain liver enzyme tests prior to initiating therapy. Monitor INR if added to warfarin, another coumarin anticoagulant or fluindione. Perform LFTs before treatment, & 6 & 12 wk thereafter; every 6 mth in patients regularly taking this drug. Concomitant use w/ cyclosporine, fibric acid derivatives, erythromycin, clarithromycin, hepatitis C antiviral agents telaprevir, elbasvir, grazoprevir, combinations of HIV PIs including saquinavir + ritonavir, lopinavir + ritonavir, tipranavir + ritonavir, darunavir + ritonavir, fosamprenavir, & fosamprenavir + ritonavir, indinavir, nelfinavir, niacin or azole antifungals; colchicine; drugs that may decrease levels or activity of endogenous steroid hormones eg, ketoconazole, spironolactone & cimetidine; fenofibrate; digoxin; verapamil, diltiazem, nicotinic acid, amiodarone. Avoid concomitant administration w/ gemfibrozil. Not recommended in coadministration of ezetimibe w/ other fibrates. Not recommended in coadministration w/ fusidic acid. May affect ability to drive or operate machinery. Not recommended in patients w/ moderate (Child-Pugh score 7-9) or severe (Child-Pugh score >9) liver dysfunction. Females of reproductive potential should use effective contraception during treatment. Discontinue use during pregnancy. Not recommended in ped patients. Elderly.